Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients with Inflammatory Bowel Disease

Journal of Clinical Gastroenterology

Volumn 50, Issue 6, 2016, Pages 483-489

  Steenholdt, Casper ^a   Frederiksen, Madeline T ^a   Bendtzen, Klaus ^b   Ainsworth, Mark A ^a   Thomsen, Ole Ø ^a   Brynskov, Jørn ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

adalimumab; antibodies; antidrug antibodies; IBD; therapeutic drug monitoring; TNF; transiency

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; CORTICOSTEROID; INFLIXIMAB; ANTIBODY; ANTIINFLAMMATORY AGENT;

ADULT; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIMIT OF DETECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REPORTER GENE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; TIME FACTOR; TREATMENT FAILURE; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENES, REPORTER; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84975748753     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000375     Document Type: Conference Paper

References (37)

1. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212.
2. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
3. Sandborn WJ, Van AG, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.
4. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011;106: 674-684.
5. Chaparro M, Panes J, Garcia V, et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis. 2012;18:685-690.
6. Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis. 2013;7:154-160.
7. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 38:447-459.
8. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139.
9. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11:654-666.
10. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63: 919-927.
11. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20:1996-2003.
12. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13:522-530.
13. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28:1122-1126.
14. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
15. Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther. 2014;40:620-628.
16. Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in inflix-imab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20:1714-1721.
17. Roblin X, Rinaudo M, Del TE, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109: 1250-1256.
18. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72:104-109.
19. Bendtzen K. Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy. 2012; 4:1167-1179.
20. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-88.
21. Paul S, Moreau AC, Del TE, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20: 1288-1295.
22. Steenholdt C, Al-Khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2209-2217.
23. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962-971.
24. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258-1264.
25. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007;46:1828-1834.
26. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit. 2013;35: 530-538.
27. Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011;373:229-239.
28. Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109:1055-1064.
29. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011; 60:41-48.
30. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40-47.
31. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:51-58.
32. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
33. Baert F, Noman M, Vermeire S, et al. Influence of immuno-genicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
34. Steenholdt C, Bendtzen K, Brynskov J, et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. J Crohns Colitis. 2015;9:238-245.
35. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460-1468.
36. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med. 2013;15:201-211.
37. Van Schouwenburg PA, Krieckaert CL, Rispens T, et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiot-ype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis. 2013;72:1680-1686.